V.A. Miller

4.8k total citations · 2 hit papers
83 papers, 3.0k citations indexed

About

V.A. Miller is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, V.A. Miller has authored 83 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 48 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in V.A. Miller's work include Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (20 papers) and Cancer Genomics and Diagnostics (18 papers). V.A. Miller is often cited by papers focused on Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (20 papers) and Cancer Genomics and Diagnostics (18 papers). V.A. Miller collaborates with scholars based in United States, United Kingdom and France. V.A. Miller's co-authors include Mark G. Kris, Maureen F. Zakowski, Francis M. Sirotnak, Howard I. Scher, Siraj M. Ali, Arabinda K. Das, M. Rossi, Jeffrey S. Ross, William Pao and Alexa B. Schrock and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

V.A. Miller

81 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

2000 665 citations Francis M. Sirotnak, V.A. Miller et al. profile →
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

2019 441 citations Alexa B. Schrock, Ching Ouyang et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V.A. Miller United States	22	2.1k	1.6k	924	508	350	83	3.0k
Sreenivasa Nattam United States	20	1.9k 0.9×	1.0k 0.6×	760 0.8×	378 0.7×	229 0.7×	42	2.6k
Andrew Weickhardt Australia	23	2.3k 1.1×	2.3k 1.4×	967 1.0×	527 1.0×	393 1.1×	111	3.4k
Vinod Ganju Australia	24	2.0k 0.9×	906 0.6×	655 0.7×	447 0.9×	316 0.9×	94	2.7k
Vincent Haddad United Kingdom	16	1.5k 0.7×	1.3k 0.8×	907 1.0×	485 1.0×	414 1.2×	36	2.9k
J. Randolph Hecht United States	22	2.8k 1.3×	1.9k 1.1×	949 1.0×	501 1.0×	617 1.8×	78	4.2k
Davey B. Daniel United States	19	2.2k 1.1×	2.1k 1.3×	538 0.6×	688 1.4×	237 0.7×	82	3.3k
Enric Carcereny Spain	26	1.9k 0.9×	1.6k 1.0×	856 0.9×	515 1.0×	207 0.6×	183	2.9k
Tak Yun South Korea	24	1.4k 0.7×	1.3k 0.8×	598 0.6×	480 0.9×	277 0.8×	81	2.3k
Santiago Viteri Spain	31	2.1k 1.0×	2.1k 1.3×	1.3k 1.4×	903 1.8×	324 0.9×	169	3.4k
Michael Millward Australia	25	1.7k 0.8×	1.1k 0.7×	1.1k 1.2×	331 0.7×	142 0.4×	43	2.9k

Countries citing papers authored by V.A. Miller

Since Specialization

Citations

This map shows the geographic impact of V.A. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V.A. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V.A. Miller more than expected).

Fields of papers citing papers by V.A. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V.A. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V.A. Miller. The network helps show where V.A. Miller may publish in the future.

Co-authorship network of co-authors of V.A. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of V.A. Miller. A scholar is included among the top collaborators of V.A. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V.A. Miller. V.A. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schrock, Alexa B., Ching Ouyang, Jaideep Sandhu, et al.. (2019). Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Annals of Oncology. 30(7). 1096–1103. 441 indexed citations breakdown →

Álvarez, Ricardo H., Eyal Meiri, Arturo Loaiza‐Bonilla, et al.. (2018). Mutational landscape of metastatic cancers discovered from prospective clinical sequencing at community practice cancer program. Annals of Oncology. 29. viii757–viii757.

Pavlick, Dean C., Jon Chung, Julia A. Elvin, et al.. (2017). Genomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types. Annals of Oncology. 28. v595–v595. 4 indexed citations

Ikeda, Sadakatsu, Laurie M. Gay, Dean C. Pavlick, et al.. (2017). Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types. Annals of Oncology. 28. x1–x1. 3 indexed citations

Ross, Jeffrey S., Pierre Vanden Borre, Nava Almog, et al.. (2017). Comprehensive Genomic Profiling (CGP) of Thymic Gland Carcinomas. Annals of Oncology. 28. v595–v596. 6 indexed citations

Ross, Jeffrey S., Laurie M. Gay, Jo‐Anne Vergilio, et al.. (2017). Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Annals of Oncology. 28(10). 2539–2546. 82 indexed citations

Pal, Sumanta K., Neeraj Agarwal, Toni K. Choueiri, et al.. (2017). Comparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC). Annals of Oncology. 28. v297–v297. 9 indexed citations

Schrock, Alexa B., David Fabrizio, Yuxia He, et al.. (2017). Analysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs). Annals of Oncology. 28. v415–v415. 11 indexed citations

Heilmann, Andreas, Alexa B. Schrock, Jie He, et al.. (2017). Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia. Leukemia. 31(9). 1989–1992. 13 indexed citations

10.

Ross, Jeffrey S., et al.. (2017). P2.02-016 Pulmonary Sarcomas: A Comprehensive Genomic Profiling Study. Journal of Thoracic Oncology. 12(11). S2104–S2104. 1 indexed citations

11.

Frampton, Garrett M., et al.. (2016). Assessment and comparison of tumor mutational burden and microsatellite instability status in >40,000 cancer genomes. Annals of Oncology. 27. vi15–vi15. 3 indexed citations

12.

Stephens, Philip J., Travis Clark, Mark Kennedy, et al.. (2016). Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors. Annals of Oncology. 27. vi401–vi401. 2 indexed citations

13.

Ross, Jeffrey S., Laurie M. Gay, Julia A. Elvin, et al.. (2016). Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression. Annals of Oncology. 27. vi70–vi70. 2 indexed citations

14.

Chung, Christine H., Violeta Beleva Guthrie, David L. Masica, et al.. (2015). Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Annals of Oncology. 26(6). 1216–1223. 147 indexed citations

15.

Sharman, Jeff P., Juliann Chmielecki, Deborah Morosini, et al.. (2014). Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 14(5). e161–e163. 41 indexed citations

16.

Ross, Jeffrey S., Siraj M. Ali, Gary A. Palmer, et al.. (2013). Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecologic Oncology. 130(3). 554–559. 72 indexed citations

17.

Grommes, Christian, Geoffrey R. Oxnard, Mark G. Kris, et al.. (2011). "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncology. 13(12). 1364–1369. 285 indexed citations

18.

Glezerman, Ilya, Mark G. Kris, V.A. Miller, Surya V. Seshan, & Carlos D. Flombaum. (2009). Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clinical Nephrology. 71(2). 130–139. 81 indexed citations

19.

Rigas, James R., Mark G. Kris, V.A. Miller, et al.. (1999). Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. Annals of Oncology. 10(5). 601–603. 8 indexed citations

20.

Willman, Cheryl L., Carleton C. Stewart, V.A. Miller, T Yi, & T. B. Tomasi. (1989). Regulation of MHC class II gene expression in macrophages by hematopoietic colony-stimulating factors (CSF). Induction by granulocyte/macrophage CSF and inhibition by CSF-1.. The Journal of Experimental Medicine. 170(5). 1559–1567. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact